Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pediatric Leukemia
100%
Leukemia Progression
100%
Genetic Changes
100%
Epigenetic Modification
100%
Acute Myeloid Leukemia
66%
Leukemia Patients
66%
Patient Stratification
50%
Pediatric Cancer
50%
Regulatory Interactions
33%
Overall Survival Rate
33%
Leukemia
33%
Poor Prognosis
16%
Cancer Biology
16%
5-year Survival
16%
High Dose
16%
Computational Biology
16%
Epigenetics
16%
Therapy Intensity
16%
Work Procedures
16%
Cytarabine
16%
Combination of Therapies
16%
Optimal Intensity
16%
Recurrent mutation
16%
Regulatory Landscape
16%
Oncology Unit
16%
Over 40
16%
Daunorubicin
16%
Leukemia Subtype
16%
Remission
16%
Treatment Regime
16%
Changes in Gene Expression
16%
Good Prognosis
16%
Somatic mutation
16%
Patient's Will
16%
Optimal Combination
16%
National Priorities
16%
Pediatric Oncology
16%
Chromosomal Rearrangements
16%
FMS-like Tyrosine Kinase 3 (FLT3)
16%
Acute Lymphoblastic Leukemia
16%
Gene Regulation
16%
Global Statistics
16%
Cancer Progression
16%
Interaction Patterns
16%
Poor Outcome
16%
Long-term Adverse Effects
16%
Overtreatment
16%
Patient Samples
16%
Regulatory Elements
16%
Patient Prognosis
16%
Drug Trials
16%
Chromatin Interactions
16%
Relapse Rate
16%
Khalifa
8%
Current Treatment
8%
Omics Approaches
8%
Cancer Cases
8%
Substrate Integrated Dielectric Resonator Antenna (SIDRA)
8%
Quality of Life
8%
Disease Progression
8%
Artificial Intelligence Techniques
8%
Qatar
8%
Medicine and Dentistry
Pediatric Acute Myeloid Leukemia
100%
Acute Myeloid Leukemia
80%
Leukemia
60%
Overall Survival
40%
Adverse Drug Reaction
20%
Somatic Mutation
20%
Cytarabine
20%
Liposomal Daunorubicin
20%
Antiinfective Agent
20%
Childhood Cancer
20%
Acute Lymphoblastic Leukemia
20%
Epigenomics
20%
Gene Expression Regulation
20%
Drug Megadose
20%
Survival Rate
20%
Cancer Growth
20%
Recurrence Risk
20%
Disease Exacerbation
10%
Diagnosis
10%
Drug Screening
10%
Tamsulosin
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Leukemia
33%
Malignant Neoplasm
22%
Overall Survival
22%
Survival Rate
11%
Tamsulosin
11%
Daunorubicin
11%
Adverse Drug Reaction
11%
Remission
11%
Childhood Cancer
11%
Cytarabine
11%
Antiinfective Agent
11%
Acute Lymphoblastic Leukemia
11%
Recurrence Risk
11%
Cancer Growth
11%
Disease Exacerbation
5%